These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23526068)

  • 1. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.
    de Jonge C; Rensen SS; Verdam FJ; Vincent RP; Bloom SR; Buurman WA; le Roux CW; Schaper NC; Bouvy ND; Greve JW
    Obes Surg; 2013 Sep; 23(9):1354-60. PubMed ID: 23526068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.
    Stratmann B; Krepak Y; Schiffer E; Jarick I; Hauber M; Lee-Barkey YH; Fischer M; Tschoepe D
    Horm Metab Res; 2016 Sep; 48(10):630-637. PubMed ID: 27589345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes.
    Cohen R; le Roux CW; Papamargaritis D; Salles JE; Petry T; Correa JL; Pournaras DJ; Galvao Neto M; Martins B; Sakai P; Schiavon CA; Sorli C
    Diabet Med; 2013 Dec; 30(12):1482-6. PubMed ID: 23802863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
    Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
    J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
    Jirapinyo P; Haas AV; Thompson CC
    Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes.
    Rohde U; Federspiel CA; Vilmann P; Langholz E; Friis SU; Krakauer M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2017 Feb; 19(2):189-199. PubMed ID: 27696668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Obes Surg; 2018 Aug; 28(8):2187-2196. PubMed ID: 29504053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner.
    Betzel B; Koehestanie P; Homan J; Aarts EO; Janssen IM; de Boer H; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2017 Feb; 85(2):409-415. PubMed ID: 27451295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
    Rohde U
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes.
    Rodriguez L; Reyes E; Fagalde P; Oltra MS; Saba J; Aylwin CG; Prieto C; Ramos A; Galvao M; Gersin KS; Sorli C
    Diabetes Technol Ther; 2009 Nov; 11(11):725-32. PubMed ID: 19905889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner.
    de Moura EG; Martins BC; Lopes GS; Orso IR; de Oliveira SL; Galvão Neto MP; Santo MA; Sakai P; Ramos AC; Garrido Júnior AB; Mancini MC; Halpern A; Cecconello I
    Diabetes Technol Ther; 2012 Feb; 14(2):183-9. PubMed ID: 21932999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients.
    Deutsch L; Ben Haim L; Sofer Y; Gluck N; Santo E; Fishman S
    Surg Obes Relat Dis; 2018 Oct; 14(10):1561-1569. PubMed ID: 30449512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
    Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
    Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic surgery and intestinal gene expression: Digestive tract and diabetes evolution considerations.
    Rodrigues MR; Santo MA; Favero GM; Vieira EC; Artoni RF; Nogaroto V; de Moura EG; Lisboa P; Milleo FQ
    World J Gastroenterol; 2015 Jun; 21(22):6990-8. PubMed ID: 26078577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass.
    Nguyen KT; Billington CJ; Vella A; Wang Q; Ahmed L; Bantle JP; Bessler M; Connett JE; Inabnet WB; Thomas A; Ikramuddin S; Korner J
    Diabetes; 2015 Sep; 64(9):3104-10. PubMed ID: 25901097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
    Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.